SPL responds to US FDA warning letter
US Heparin maker Scientific Protein Laboratories (SPL) says it has resolved “many of the issues” addressed in the US Food and Drug Administration (FDA) warning letter it received late last month.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs